Zacks Investment Research
25 Jun 2026, 13:46 UTC · 13w ago
Verdict
Headline takes no side. We score ABCL +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
AbCellera Biologics entered a preclinical research collaboration with Jazz Pharmaceuticals to develop T-cell-engaging multispecific antibodies for GI cancers and solid tumors.
So whatThe partnership provides significant potential revenue via $56 million in upfront payments and up to $792 million in future milestone payments per program.
More positive than 93% of claims this week
AbCellera Biologics is expected to report a quarterly revenue decline of 55.5% and a quarterly loss of $0.17 per share.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 86% of claims this week
AbCellera Biologics shares rose 7.1% in the last trading session to close at $6.03.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 75% of relationship scores this week
[mutual] AbCellera and Jazz Pharmaceuticals entered a preclinical research collaboration deal to develop multispecific antibodies.
More positive than 56% of relationship scores this week
[a_to_b] Jazz Pharmaceuticals is paying AbCellera upfront payments and milestone fees for research programs.
More positive than 2% of relationship scores this week
[mutual] Both companies are identified as members of the Zacks Medical - Biomedical and Genetics industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
11h ago
+109.8%
Price agrees with the score
$12.65 vs $6.03 close before publication (Jun 24) · not market-adjusted
ABCL chart →
